Publications by authors named "Go Miyashita"
Purpose: L-[3-(18)F]-α-Methyltyrosine ((18)F-FAMT) was developed as an amino acid tracer for PET imaging to provide better specificity than 2-[(18)F]fluoro-2-deoxy-D-glucose ((18)F-FDG) PET for cancer diagnosis. We investigated the diagnostic usefulness of (18)F-FAMT in oral squamous cell carcinoma (OSCC). The correlation between tumour uptake of (18)F-FAMT and L-type amino acid transporter 1 (LAT1) expression was determined.
View Article and Find Full Text PDFArticle Synopsis
- L-3-[(18)F]-fluoro-α-methyl tyrosine ((18)F-FAMT) is a PET/CT tracer that targets cancer cells via LAT1, with a focus on diagnosing bone marrow invasion in oral squamous cell carcinoma (OSCC) compared to other imaging methods.
- In a study of 27 OSCC patients, (18)F-FDG PET/CT showed the highest sensitivity (100%), while (18)F-FAMT PET/CT exhibited the highest specificity (85.7%) among the techniques evaluated.
- The findings suggest that (18)F-FAMT PET/CT is more specific for detecting bone marrow invasion, potentially aiding in less extensive surgical interventions for patients
We report the case of 58-year-old man with pulmonary artery intimal sarcoma. He initially presented with cough, right-sided chest pain, and shortness of breath. Although the diagnosis of pulmonary embolism had been considered, chest radiograph and pulmonary perfusion scintigraphy showed a mass in the right hilum and no perfusion in the right lung.
View Article and Find Full Text PDFObjective: L-3-[¹⁸F]-fluoro-α-methyl tyrosine (FAMT) is transported into cancer cells by L: -type amino acid transporter 1 (LAT1). The purpose of the present study is to correlate the uptake of FAMT and FDG with the cellular proliferative activity measured by the Ki-67 labeling index (Ki-67 LI) in oral squamous cell carcinoma (OSCC).
Methods: Twenty-five patients with OSCC were enrolled in this study.
Objective: Clinical application of FDG-PET in head and neck cancer includes identification of metastases, unknown primary head and neck malignancy, or second primary carcinoma, and also recurrent tumor after treatment. In this study, the additional value of PET/CT fusion images over PET images alone was evaluated in patients with initial staging and follow up of head and neck malignancy.
Methods: Forty patients with suspected primary head and neck malignancy and 129 patients with suspected relapse after treatment of head and neck malignancy were included.